Leveraging Single-Cell Sequencing to Identify Highly Precise Single and Combination T-Cell Engager Targets
- Highlighting the central challenge in solid tumor T-cell engagers: identifying clean targets with high tumor specificity
- Cartography’s ATLAS platform: applying single-cell RNA sequencing to map tumor antigen expression and identify tumor-restricted antigens with broad patient coverage
- Discovery and advancement of CBI-1214, a T-cell engager targeting LY6G6D, a highly tumor-restricted colorectal cancer antigen entering the clinic in early 2026
- Extending this framework to multi-specific and AND-gated T-cell engagers through the SUMMIT platform, enabling identification of target pairs that further enhance therapeutic index